Drugs that contain Cefiderocol Sulfate Tosylate

1. Fetroja patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9238657 SHIONOGI INC Cephalosporin having catechol group
Nov, 2033

(9 years from now)

US10004750 SHIONOGI INC Salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof
Sep, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9949982 SHIONOGI INC Preparation containing cephalosporin having a catechol moiety
Sep, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 14, 2024
Generating Antibiotic Incentives Now(GAIN) Nov 14, 2029
New Indication(I-844) Sep 25, 2023

NCE-1 date: 14 November, 2028

Market Authorisation Date: 14 November, 2019

Treatment: Method of treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp) comprising administering cefiderocol sulfate tosylate


More Information on Dosage

FETROJA family patents

Family Patents